Skip to content

tabletki powlekane

DRUG17 trials

Sponsors

National Institute Of Cardiology, KRKA tovarna zdravil d.d. Novo mesto, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Medical University Of Gdansk, Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy

Conditions

000 people may be affected by HCM3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. HenceAF occurence is even higherAcute Coronary Syndrom (ACS)Chronic obstructive pulmonary disease (COPD)Compulsive Sexual Behaviour DisorderCoronary Artery DiseaseCoronary Atherosclerosis

Phase 2

Randomized, double-blind, multicenter, parallel group, placebo-controlled study to evaluate the efficacy and safety of phenofibrate treatment on the functions of beta cells in children and adolescents with newly diagnosed of type 1 diabetes
RecruitingCTIS2024-517483-34-00
Medical University Of WarsawEvaluation of the effect of phenofibrate on the functions of beta cells in children with new diagnosis of type 1 diabetes
Start: 2022-09-21Target: 98Updated: 2025-06-10
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of tianeptine in the treatment of covid fog symptoms in patients after COVID-19 with the study of the pathophysiology of the phenomenon using positron emission tomography, biochemical, immunological and electrophysiological parameters (COVMENT).
Not yet recruitingCTIS2024-510790-19-00
Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyCovid fog - a dysfunctional condition characterized by slowed thinking, difficulty remembering, disorientation +1
Target: 140Updated: 2024-12-02
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of iN1011-N17-02 in Patients with Post herpetic Neuralgia (PHN)
CompletedCTIS2024-518747-38-00
iN Therapeutics Co. Ltd.Post herpetic Neuralgia
End: 2025-09-01Target: 66Updated: 2025-07-14
Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial
Not yet recruitingCTIS2025-521985-82-00
Woerwag Pharma GmbH & Co. KGDiabetic sensorimotor polyneuropathy (DSPN)
Target: 136Updated: 2026-02-18

Phase 3

The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease.
Active, not recruitingCTIS2024-511894-32-00
Uniwersytet Jagiellonski Collegium MedicumIschemia of the lower limbs in the course of obstructive artery disease
Start: 2021-08-19Target: 200Updated: 2024-07-01
The use of sildenafil in patients with univentricular heart after Fontan operation - a pilot SINFON-POL study.
RecruitingCTIS2023-503913-31-01
National Institute Of Cardiologyand above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, and in multi-centre studies. Among other things +16
Start: 2025-06-27Target: 60Updated: 2025-07-22
Pharmacological treatment of compulsive sexual behaviour disorder
WithdrawnCTIS2024-514490-22-00
Centrum Medyczne Ksztalcenia PodyplomowegoCompulsive Sexual Behaviour Disorder
Target: 410Updated: 2024-09-30
Evaluation of safety and efficacy of two ticagrelorbased de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicenter, double-blind ELECTRA RCT study.
Active, not recruitingCTIS2024-518090-34-00
Nicolaus Copernicus UniversityAcute Coronary Syndrom (ACS)
Start: 2022-02-07Target: 4500Updated: 2024-11-24
FORMA – a multicentre randomized-controlled trial to evaluate the efficacy and safety of ketoanalogues of essential amino acids in prophylaxis of protein-energy wasting in nephrotic syndrome.
RecruitingCTIS2024-517880-22-00
Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyProtein-energy wasting in nephrotic syndrome
Start: 2023-01-04Target: 150Updated: 2026-01-09
Non-commercial clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Clinical part: Atorvastatin effect on reduction of COPD exacerbations. Genomic part: Assessment of immunobiology of COPD related lung carcinoma and inflammatory pathways activation based on gene expression profiles of the peripheral blood leukocytes (PBLs) and peripheral blood mononuclear cells (PBMCs) from smokers with chronic obstructive pulmonary disease (COPD).
RecruitingCTIS2024-516714-37-00
Medical University Of BialystokChronic obstructive pulmonary disease (COPD)
Start: 2022-01-19Target: 480Updated: 2024-12-02
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved ejection fraction
CompletedCTIS2024-515061-33-00
Medical University Of GdanskDepressive-anxiety states in people with heart failure with preserved ejection fraction
Start: 2024-03-22End: 2025-12-05Target: 485Updated: 2025-07-24
Optimal medical treatment of uncontrolled hypertension. OPTIMAL-HT
RecruitingCTIS2024-517628-20-00
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczyhypertension, Overpressure
Start: 2023-10-24Target: 2500Updated: 2025-04-29
The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement
RecruitingCTIS2023-509111-89-00
Medical University Of GdanskSystemic mastocytosis with a slow course and involvement of the skin
Start: 2025-10-15Target: 66Updated: 2025-06-30

Phase 4

Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
CompletedCTIS2023-508743-43-00
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy000 people may be affected by HCM, 3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. Hence, AF occurence is even higher +25
End: 2025-09-16Target: 725Updated: 2024-09-16
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with coronary artery disease and preDiabetES. A randomised clinical trial (CASCADES)
RecruitingCTIS2023-508525-27-00
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut BadawczyCoronary Artery Disease, Coronary Atherosclerosis, Coronary Heart Disease +1
Start: 2025-07-10Target: 300Updated: 2025-08-27
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial
CompletedCTIS2023-505875-56-00
KRKA tovarna zdravil d.d. Novo mestoKnee osteoarthritis
Start: 2025-05-21End: 2025-09-17Target: 38Updated: 2025-10-21
A multicenter, prospective clinical TRrial evaluating patient’s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction. TRUST Trial on Responsible Use and Self-assessed Treatment.
Not yet recruitingCTIS2025-522923-81-00
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Erectile dysfunction
Target: 200Updated: 2026-01-26